MedPath

Antibacterial utilization study in patients admitted to medical intensive care unit of major hospital of india

Phase 4
Completed
Conditions
Patients admitted to Medicine Intensive Care Unit
Registration Number
CTRI/2014/12/005297
Lead Sponsor
Seth GS Medical College and KEM Hospital
Brief Summary

**Demographics:**

A total of 700 participants were recruited across the five centers (140per centers). The median age across centers was 48 (13, 92). There were 424(60.57%) male and 276 (39.43%) female.**Indicators:**

In public (KEM andNair) and government-Tata  (autonomous)hospitals, the average number of drugs were significantly higher compared to private(Bombay and Subharti ) hospitals; however, average number of antibacterials ingovernment hospital were significantly higher compared to public and privatehospitals. The average number of antibacterials prescribed in KEMHospital (2.93 ± 2.12) were significantly higher than the Nair Hospital (1.28±0.53); although both the hospitals are public hospitals. Percentage of antibacterials prescribed at publichospitals were not significantly higher than the government hospital andprivate hospitals (p=0.2009); however, the percentage of antibacterialsprescribed at Nair hospital were significantly lower than the other centers(p<0.0001).  Percentage of patientsreceived antibacterials were significantly different between public, governmentand private hospitals (p=0.0014) and between the individual centers (p=0.0003).  Private hospitals had lower percentage ofantibacterial agents prescribed by generic name (P< 0.0001). There was no significant difference inintravenous use (p=0.2586) ofantibacterials and the fixed dose combinations (p=0.91).  At government and private hospitals, none ofthe patient received antibacterial from hospital pharmacy.

Nair Hospital had significantly lower percentage ofpatients in whom antibacterial agent was changes over the course of MICUadmission as well as had very low percentage of antibacterial treatment as persensitivity pattern (p<0.0001). Subharti Hospital had leastpercentage of patients who received antibacterial treatment as per sensitivitypattern and is statistically significant (< 0.0001). KEM Hospital had longer average length ofantibacterial treatment and longer length of empirical use of antibacterials aswell as longer length of MICU stay compared to all other centers. BombayHospital and Tata hospital had highest per patient cost of antibacterialtreatment. Public hospital had significantly lower per patient cost ofantibacterial treatment (<0.0001). Significantly higher mortality was observed inpublic and government hospitals compared to private hospitals (< 0.0001). Penicillins, glycopeptides,Beta-Lactams and Polymyxin-E were comparatively largely prescribed at KEM andTata hospitals. Cephalosporin’s use was high at public hospitals. At Bombayhospital flouroquinolones was largely prescribed. Prescription of Vancomycin and Colistin was foundto be higher at KEM and Tata hospital.

**Pooled data:**

Patients in MICUreceived as many as 10.90 (± 6.83) drugs, of which only 1.98 ± 1.36 (16.11 %)were the antibacterials. Over the study period, 92.42 % patients receivedantibacterials of which 41.00% antibacterials were prescribed by generic name.A total of 93.89 % antibacterials prescribed intravenously. Only 28%antibacterials were prescribed from hospital pharmacy. Change of antibacterialagent was required in 31.75 % patients and only 3.54 % were prescribed as FDCs.The average length of MICU stay was 6.33 (±7.31), average length ofantibacterial treatment was 6.38 (±7.54) and average duration of empiricaltreatment was 5.94 (±5.35). Across the centers average antibacterial cost perpatient was 7781.58 (± 4636.054). A total of 88 culture tests were positive amongst212 patients, from which 71 (80.68%) patients received antibacterials as persensitivity pattern.

A total of 293.41 DDDs/100 bed days’ antibacterials consumed overthe study period.  Large amount ofantibacterials consumed at KEM (91.93 DDDs/100 bed days), Tata (94.60 DDDs/100bed days) and Bombay (75.87 DDDs/100 bed days) hospitals compared to Nair(16.90 DDDs/100 bed days) and Subharti (14.11 DDDs/100 bed days) hospitals.Penicillins (KEM-18.79 DDDs/100 bed days, Bombay-23.48 DDDs/100 bed days) andcephalosporins (KEM=23.67 DDDs/100 bed days, Bombay=22.28 DDDs/100 bed days)were largely consumed at KEM and Bombay, while the glycopeptides (Tata-8.73DDDs/100 bed days and KEM-7.08 DDDs/100 bed days) and B-lactams (Tata-32.6DDDs/100 bed days and KEM-14.14 DDDs/100 bed days)  were highly consumed at Tata  and KEM Hospital.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
700
Inclusion Criteria

Patients either gender of above 14 years old admitted to Medicine Intensive Care Unit.

Exclusion Criteria

Not willing to participate in the study.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Proportion of patients receiving either vancomycin or colistin or bothAll the outcomes will be assessed at the end of the study
2.Prescribed daily dose (PDD) of antibacterial agentsAll the outcomes will be assessed at the end of the study
3.Defined daily doses (DDDs) per 100 bed-days for individual antibacterial agentsAll the outcomes will be assessed at the end of the study
Secondary Outcome Measures
NameTimeMethod
1.Proportion of antibacterial agents prescribed over the study period2.To assess the proportion of antibacterials prescribed on the basis of culture and sensitivity report

Trial Locations

Locations (5)

Bombay Hospital and Medical Research Centre

🇮🇳

Mumbai, MAHARASHTRA, India

Seth GS Medical College and KEM Hospital

🇮🇳

Mumbai, MAHARASHTRA, India

Subharti Medical College and Hospital

🇮🇳

Meerut, UTTAR PRADESH, India

T N Medical college and BYL Nair Charitable Hospital Mumbai Central Mumbai

🇮🇳

Mumbai, MAHARASHTRA, India

Tata Memorial Hospital

🇮🇳

Mumbai, MAHARASHTRA, India

Bombay Hospital and Medical Research Centre
🇮🇳Mumbai, MAHARASHTRA, India
Dr Sanjay Wagle
Principal investigator
02222091325
scwagle@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.